Search results for "Lung"

showing 10 items of 2389 documents

1063P Profiling of peripheral T cell receptor beta chain repertoire in non-small cell lung cancer (NSCLC) patients treated with anti-PD1

2020

Oncologybusiness.industryRepertoireCancer researchmedicinenon-small cell lung cancer (NSCLC)HematologyT-Cell Receptor Beta ChainAnti pd1medicine.diseasebusinessPeripheralAnnals of Oncology
researchProduct

Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer

2017

Oncologybusiness.industrymedicineCancer researchHematologyNon small cellLung cancermedicine.diseasebusinessAnnals of Oncology
researchProduct

Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways

2017

Oncologybusiness.industrymedicineCancer researchHematologyNon small cellSignal transductionDifferential expressionLung cancermedicine.diseasebusinessAnnals of Oncology
researchProduct

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.

2021

To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC harboring EGFR mutations.A partitioned survival model was developed to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) from the perspective of the Spanish National Health System. Two Bayesian NMAs were performed independently, by using the polynomial fraction method to fit Kaplan-Meier curves for overall survival and progression-free survival. Deterministic and probabilistic sensitivity analyses were performed to evaluate the uncertainty.The ICER was calculated for the fou…

Oncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLung NeoplasmsCost effectivenessAfatinibCost-Benefit AnalysisAfatinibchemistry.chemical_compoundErlotinib HydrochlorideGefitinibInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansheterocyclic compoundsPharmacology (medical)OsimertinibLung cancerneoplasmsProtein Kinase Inhibitorsbusiness.industryHealth PolicyBayes TheoremGefitinibGeneral MedicineCost-effectiveness analysismedicine.diseaseDacomitinibrespiratory tract diseasesErbB ReceptorschemistryMutationErlotinibbusinessmedicine.drugExpert review of pharmacoeconomicsoutcomes research
researchProduct

Breath testing as a method for detecting lung cancer

2014

Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air of cancer patients were discovered some volatile organic compounds - possible candidates for cancer markers. However, these compounds were not specific for cancer cells. At the same time, integrative approaches used to analyze the exhaled breath have demonstrated high sensitivity and specificity of this method for lung cancer diagnosis. Such integrative approaches include detect…

Oncologyelectronic nosemedicine.medical_specialtyPathologyLung Neoplasms:MEDICINE [Research Subject Categories]Sensitivity and SpecificityGas Chromatography-Mass SpectrometryBreath testingInternal medicineCancer screeningBiomarkers TumormedicineHumansPharmacology (medical)Lung cancerEarly Detection of CancerNeoplasm StagingVolatile Organic CompoundsElectronic nosecancer diagnosticsbusiness.industryCancerExhalationexhaled breath analysismedicine.diseaselung cancerBreath TestsOncologyBreath gas analysisExhalationcancer screeningGas chromatographybusiness
researchProduct

Plasma circulating miRNAs as diagnostic and prognostic biomarkers in alpha-1 antitrypsin deficiency

2019

Introduction: Alpha-1 antitrypsin (AATD) deficiency is an inherited condition that leads to decreased circulating AAT levels, significantly increasing the risk of lung and liver disease. AATD is underdiagnosed. Severity of symptoms in AATD patients are highly variable and neither protein levels nor phenotype are sufficient to identify which patients will develop lung and/or liver disease. Therefore, new strategies and biomarkers for early diagnosis and prognosis of the disease are needed. Rationale and Aims: MicroRNAs (miRNAs) regulate gene expression and have been associated with the pathogenesis of various lung and liver diseases. Circulating miRNAs may serve as diagnostic and prognostic …

Oncologymedicine.medical_specialtyAlpha 1-antitrypsin deficiencyLungbusiness.industryDiseasemedicine.diseasePhenotypePathogenesisLiver diseasemedicine.anatomical_structureInternal medicinemicroRNAGene chip analysismedicinebusinessMolecular pathology and funct. genomics
researchProduct

Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study

2011

Abstract Background and purpose Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Materials and methods Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m2 per day and increased by s…

Oncologymedicine.medical_specialtyCancer ResearchRadiation-Sensitizing AgentsLung Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsNSCLCMedicine & Public Health; Hematology; Oncology; Internal Medicine; Cancer Research03 medical and health sciencesFludarabine0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineCombined Modality TherapyHumansConcurrent fludarabine and radiotherapy030304 developmental biologyNeoplasm Staging0303 health sciencesOriginal PaperHematologyNucleoside analoguebusiness.industryRadiotherapy DosageGeneral MedicineAdenine nucleosideRadiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCNucleoside analoguemedicine.diseaseCombined Modality Therapy3. Good healthFludarabinerespiratory tract diseasesClinical trialRadiation therapyOncology030220 oncology & carcinogenesisRadiotherapy phase I studybusinessFludarabine; NSCLC; Nucleoside analogue; Concurrent fludarabine and radiotherapy; Radiotherapy phase I study; Radiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCVidarabinemedicine.drug
researchProduct

Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer

2013

Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms of folate pathway genes for pemetrexed metabolism have not been fully elucidated yet. The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. miR-22, miR-24, …

Oncologymedicine.medical_specialtyChemotherapyPhysiologybusiness.industrymedicine.medical_treatmentClinical BiochemistryCellCell BiologyBioinformaticsmedicine.diseasemedicine.anatomical_structurePemetrexedInternal medicinemicroRNAmedicineClinical significancebusinessLung cancerProgressive diseaseWhole bloodmedicine.drugJournal of Cellular Physiology
researchProduct

Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy

2019

Abstract Background Lung cancer is the leading cause of cancer-related mortality worldwide. At diagnosis, 70% of patients present advanced disease being chemotherapy the standard of care. Although, specific tumour biomarkers that allow a better treatment selection and monitoring is absent at the moment. Enumeration and characterization of circulating tumor cells (CTCs) have the potential to perform as a prognostic biomarker for a precision medicine approach to lung cancer care. The present study was conducted to validate the characterization CTCs from patients with advanced Non-small cell lung cancer (NSCLC) as a valuable tool for anticipating the disease evolution and the therapy response.…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentHematologyPrecision medicinemedicine.diseaseCirculating tumor cellOncologyInternal medicinemedicineAdvanced diseasePrognostic biomarkerChristian ministryNon small cellLung cancerbusinessAnnals of Oncology
researchProduct

Snps in Angiogenic Factors As Predictive Markers for Outcome in Patients (P) with Advanced Non-Squamous Nsclc (NS-NSCLC) Treated with Carboplatin, Pa…

2015

Oncologymedicine.medical_specialtyGroup trialPredictive markerBevacizumabbusiness.industryHematologymedicine.diseaseCarboplatin/paclitaxelCarboplatinchemistry.chemical_compoundOncologychemistryPaclitaxelNon squamousInternal medicinemedicineLung cancerbusinessmedicine.drugAnnals of Oncology
researchProduct